FLOVENT HFA INHALER FLUTICASONE 250MCG 60 DOSES

Description

Anti-inflammatory-steroidal.

Asthma: FLIXOTIDE® has a pronounced anti-inflammatory effect on the lungs.

Reduces asthma symptoms and exacerbations in patients previously treated with a bronchodilator alone or with other prophylactic therapy.

Patients with severe asthma require regular medical evaluation, as this condition can lead to death. These patients present constant symptoms and frequent exacerbations, as well as limited physical capacity and PEF values ​​below 60% of the expected value at baseline, with a variability greater than 30%; these patients usually do not fully recover after using a bronchodilator. These patients will require high-dose inhaled (see Dosage and Route of Administration) or oral corticosteroid therapy. If there is a sudden worsening of symptoms, an increase in the dosage of corticosteroids may be required, which should be administered under urgent medical supervision.

• Adults:

Prophylactic treatment in:

– Mild asthma (PEF values ​​above 80% of the expected value at baseline, with a variability less than 20%): Patients who on more than one occasion require intermittent symptomatic medication, with a bronchodilator, for the treatment of their asthma.

– Moderate asthma (PEF values ​​60-80% of the expected value at baseline, with a variability of 20-30%): Patients who regularly require anti-asthma medication, as well as patients with unstable or worsening asthma who are under treatment with any currently available prophylactic medication, or just a bronchodilator.

– Severe asthma (PEF values ​​below 60% of the expected value at baseline, with a variability greater than 30%): Patients with chronic severe asthma. By introducing therapy with any FLIXOTIDE® inhalation formulation, many patients who rely on systemic corticosteroids to adequately control their symptoms could significantly eliminate or reduce their requirement for oral corticosteroids.

• Children:

Any child who requires medication for the prevention of asthma, including those patients who are not being controlled with any currently available prophylactic medication.

Chronic Obstructive Pulmonary Disease (COPD): FLIXOTIDE® is indicated for the management of COPD when used in combination with long-acting bronchodilators (eg long-acting beta agonists [LABAs]).